Detalhe da pesquisa
1.
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Blood
; 131(15): 1704-1711, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29305552
2.
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
N Engl J Med
; 374(4): 311-22, 2016 Jan 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26639348
3.
Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.
Haematologica
; 104(11): 2258-2264, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923097
4.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol
; 19(1): 65-75, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29246803
5.
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Lancet Oncol
; 18(2): 230-240, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28089635
6.
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Hematol Oncol
; 35(4): 679-684, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27982454
7.
A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy.
NMR Biomed
; 24(9): 1169-80, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21432928
8.
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Lancet Oncol
; 11(12): 1149-59, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21094089
9.
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma.
Clin Cancer Res
; 13(22 Pt 1): 6689-95, 2007 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18006769
10.
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
J Clin Pharmacol
; 57(4): 484-492, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27558232
11.
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Clin Pharmacokinet
; 56(5): 515-523, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27638334
12.
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments.
Clin Ther
; 39(2): 359-367, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28161120
13.
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
J Clin Oncol
; 35(8): 826-833, 2017 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28095146
14.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer.
J Clin Oncol
; 23(22): 5188-97, 2005 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16051960
15.
Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
AAPS J
; 18(5): 1192-1202, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27233802
16.
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
J Clin Oncol
; 21(4): 679-89, 2003 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12586806
17.
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Clin Cancer Res
; 9(8): 2965-72, 2003 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12912943
18.
Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
J Clin Oncol
; : JCO1800359, 2018 Oct 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30359156
19.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med
; 19(2): 202-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23291630
20.
Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.
Clin Cancer Res
; 18(11): 3163-9, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22496272